Join our daily newsletter At The Bell to receive exclusive market insights
- Race Oncology signs a supply agreement with Trialog Clinical Trials for its phase two Acute Myeloid Leukemia (AML) trial
- The phase two trial will be at the Chaim Sheba Medical Centre in Israel, where 29 patients will be treated with Race’s Bisantrene drug in a three-drug combination
- Under the agreement, Trialog will supply the trial drugs, which includes Bisanntrene, as well as provide clinical services to Race and Chaim Sheba
- Just as the market opens, Race is trading at $3.77 per share
Race Oncology (RAC) has signed a contract with Israel company, Trialog Clinical Trials, to support its phase two Acute Myeloid Leukemia (AML) trial.
In this trial, 29 patients will use Race’s Bisantrene drug in a novel three-drug combination which have previously showed superior efficacy in AML cells.
AML is a type of cancer in which the bone marrow makes abnormal myeloblasts — a type of white blood cell — red blood cells, or platelets. This type of cancer usually gets worse quickly if it is not treated.
The trial will be at the Chaim Sheba Medical Centre in Israel, has received human ethics approval and will be supervised by Professor Arnon Nagler.
Trialog will supply the trial drugs, which include Bisanntrene, and provide clinical services to Race and Chaim Sheba.
This supply agreement has a maximum cost of around US$801,000 (about A$1 million) and will be invoiced in line with patient enrolment over the period.
The first patient is expected to be treated in the third quarter of the current year 2021.
“Race Oncology looks forward to advising on the initiation of this trial in the near future, once it has executed the trial contract with the Chaim Sheba Medical Center,” the company said.
The phase two AML trial will run in parallel with a separate Australian phase two trial in patients with extramedullary AML.
Just as the market opens, Race is trading at $3.77 per share at 10:00 am AEST.
